Join Insilico Medicine at NeurIPS 2025: Generative AI advances for drug discovery and development
Insilico Medicine, a clinical-stage, generative AI-driven biotech, will participate in NeurIPS 2025 in San Diego, USA, December 2-7, 2025. The team will share practical progress on pharma superintelligence and present how generative models are shortening cycles from target selection to preclinical candidates.
Where to find Insilico at NeurIPS
- Conference: NeurIPS 2025, San Diego, December 2-7, 2025
- Workshop: "AI Virtual Cells and Instruments: A New Era in Drug Discovery and Development"
- Date and venue: Saturday, December 6, 2025, San Diego Convention Center
- Participants: Alex Zhavoronkov, PhD (Founder and CEO), and Petrina Kamya, PhD (Global Head of AI Platforms), with Insilico's AI and CADD teams
What to expect
Insilico will preview its "AI for Science Superintelligence" concept, planned for launch next year. Built over the past twelve months, it integrates modern machine learning, deep learning, and generative methods to address hard problems across computational biology, medicinal chemistry, clinical research, and longevity science.
The team will also discuss its pharma superintelligence direction and recent preprints: TargetPro and Target Benchmark - a biology superintelligence system for de-risking and pipeline prioritization - and LEGION, a workflow for systematic chemical space exploration. Sessions will focus on practical workflows and measurable outcomes for therapeutic discovery and optimization.
Why this matters for researchers
- Cycle-time compression: traditional early discovery often takes 2.5-4 years; Insilico reports 12-18 months from project initiation to preclinical candidate (PCC) nomination.
- Lean synthesis: 60-200 molecules synthesized and tested per program on average.
- Decision support: biology superintelligence (TargetPro/Benchmark) for target selection and prioritization; chemistry workflows (LEGION) to explore chemical space methodically.
- End-to-end mindset: AI-first discovery coupled with automated labs to reduce iteration lag and improve data quality.
Progress to date
- First described the use of generative AI for novel molecule design in a peer-reviewed journal in 2016; expanded since then toward pharmaceutical superintelligence.
- 20 preclinical candidates nominated with compressed timelines and focused synthesis campaigns.
- 200+ peer-reviewed publications since 2014.
- Ranked among the Top 100 global corporate institutions in the Nature Index "2025 Research Leaders" for biological and natural sciences publications.
About Insilico Medicine
Insilico Medicine is a global AI-driven biotech company using its proprietary Pharma.AI platform and an advanced automated laboratory to accelerate drug discovery. The company is progressing programs across fibrosis, oncology, immunology, pain, and obesity/metabolic disorders, and is extending its platform to adjacent areas including advanced materials, agriculture, nutrition, and veterinary medicine.
Learn more
- Conference details: NeurIPS 2025
- Company site: insilico.com
Your membership also unlocks:
